Talis Biomedical (TLIS)
(Delayed Data from NSDQ)
$9.15 USD
+0.12 (1.36%)
Updated Jun 7, 2024 03:43 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TLIS 9.15 +0.12(1.36%)
Will TLIS be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for TLIS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TLIS
Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates
Halozyme Therapeutics (HALO) Q1 Earnings and Revenues Miss Estimates
TLIS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates
MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates
Other News for TLIS
Tracking David Einhorn's Greenlight Capital Portfolio - Q1 2024 Update
TLIS Stock Earnings: Talis Biomedical Reported Results for Q1 2024
Talis: Q1 Earnings Snapshot
Talis Biomedical Secures Interim CFO Amidst Corporate Changes
TLIS Stock Earnings: Talis Biomedical Reported Results for Q4 2023